CN103861107A - Pharmaceutical composition and uses thereof - Google Patents
Pharmaceutical composition and uses thereof Download PDFInfo
- Publication number
- CN103861107A CN103861107A CN201410075924.8A CN201410075924A CN103861107A CN 103861107 A CN103861107 A CN 103861107A CN 201410075924 A CN201410075924 A CN 201410075924A CN 103861107 A CN103861107 A CN 103861107A
- Authority
- CN
- China
- Prior art keywords
- tumor
- cell
- pharmaceutical composition
- exosomes
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses a pharmaceutical composition and uses thereof. The pharmaceutical composition comprises a DNA methyltransferase inhibitor and a histone deacetylase inhibitor. The invention also discloses new uses of the pharmaceutical composition. The pharmaceutical composition is used to treat tumor cells together to obtain an exosomes tumor vaccine. The invention also discloses a method for preparing a tumor vaccine by using the pharmaceutical composition. The method comprises the following steps of using procaine and MS-275 to treat the tumor cells, and separating and purifying exosomes secreted by the tumor cells. The pharmaceutical composition disclosed by the invention improves the therapeutic effect of the exosomes tumor vaccine, and has an important clinical application value.
Description
Technical field
The present invention relates to a kind of medical composition and its use, be specifically related to a kind of pharmaceutical composition and preparing the new purposes of tumor vaccine, relate to more specifically a kind of pharmaceutical composition that comprises procaine and MS-275 and the purposes at preparation exosomes tumor vaccine thereof.
Background technology
Procaine (procaine), chemical name 4 one amino benzoic Acid 2-(lignocaine) second vinegar, it is a kind of common local anaesthetics of having used clinically last 100 years, this medicine can make cell membrane stability, reduce its permeability to ion, when neural impulse is reached, sodium, potassium ion can not pass in and out cell membrane and produce depolarization and action potential, thereby produce local anesthetic action.In addition, procaine is also widely used in the middle of the treatment of clinical departments numerous disease, as the clinical pertussis that is used for the treatment of in department of pediatrics, at clinical indomethacin, the purple paralysis of anaphylaxis, skin pruritus, the neurodermatitis of being used for the treatment of of department of dermatologry, be used for the treatment of cervix uteri difficult labour, cervical edema department of obstetrics and gynecology clinical, hasten parturition, be used for the treatment of pancreatitis Gastroenterology dept. clinical, in the clinical spitting of blood etc. that is used for the treatment of of Pneumology Department.Although procaine also has anticancer effect, this needs the higher desirable drug effect of concentration competence exertion, and he is restricted in application in this regard.
MS-275 is that a kind of novel histone removes second phthalein enzyme inhibitor (Histone deacetylase inhibitor; HDACIs); HDACIs is by the activity of inhibition of histone deacetylase; change the Acetylation Level of histone; and then change chromatin Structure and function; thereby that removes special gene transcribes inhibition, the expression of controlling gene.MS-275 belongs to benzamides Antibiotic FR 901228, and he is combined with zinc ion using Benzoylamide group as functional group, plays a role.
In recent years, tumor is as a kind of disease of serious threat people life, its Therapeutic Method has become numerous researchers and has been devoted to the problem of studying, along with immunology, cytobiology and molecular biological develop rapidly, after tumor operation, radiotherapy and the large therapy of chemotherapy three, the Biotherapeutics of tumor has become the fourth-largest therapy.Tumor biotherapy comprises immunization therapy, gene therapy, stem-cell therapy, inducing tumor cell differentiation and apoptosis, suppresses tumor neogenetic blood vessels treatment etc.Immunization method treatment tumor, because its toxicity receives much concern compared with low, the wherein development of the tumor vaccine focus that people pay close attention to especially.
Tumor vaccine is mainly by activating patient's autoimmune system, utilize specific cellular immunity and the humoral immune reaction of tumor cell or tumor antigen material induction body, the anti-cancer ability of enhancing body, stops growth, diffusion and the recurrence of tumor, to reach the object of removing or controlling tumor.Tumor vaccine is broadly divided into tumour-cell vaccine, tumor antigen and Antigens molecular vaccine, nucleic acid vaccine, recombinant virus, pathogenic bacteria vaccine and dendritic cell (dendritic cell, DC) vaccine.Tumour-cell vaccine is to extract tumor cell from body tumor tissues, makes tumor cell lose oncogenicity, but still keep its immunogenicity after inactivation treatment, then body is carried out to immunity; Tumor antigen and Antigens molecular vaccine are the vaccination patient induce immune responses that utilizes tumor antigen or class antigen determinant polypeptide, anti-idiotype antibody to prepare; Nucleic acid vaccine refers to using the plasmid that contains certain antigenic protein gene sequence of encoding as vaccine, directly import in zooblast, by the re-recording system synthetic antigen albumen of host cell, induction host produces the immunne response to this antigen protein, obtains corresponding immunoprotection thereby make to be vaccinated animal; Recombinant virus, pathogenic bacteria vaccine and dendritic cell vaccine refer to that people, by carrying the virus inoculation patient of gene of codes for tumor antigen, cytokine, costimulatory molecules, bring out the immunne response of body for tumor by their expression in vivo; Dendritic cell vaccine refers to that the dendritic cell that derive from bone marrow that are activated are at the high-caliber MHC I of cell surface expression, MHC II and ICAM and B7, and can activate T cells propagation, induce immune response.
Although a lot of to the correlational study of tumor vaccine both at home and abroad, but that up to the present makes a breakthrough is rare, the subject matter existing has: DNA is imported to specific cells, and to express this technology still immature, and uses the safety issue of foreign DNA not yet to solve; Because tumor cell presents height heterogeneity, belong on multiple oncocytes of same type tumor and can express different antigen, the T cell being activated by a kind of tumor antigen can only kill and wound a part of tumor cell, and the oncocyte of not expressing this antigen can not be killed and wounded; Although tumour-cell vaccine can comprise most tumor antigen, current research shows that the effect of its activated T cell is limited, and the effect that sets it as vaccine is unsatisfactory.
Exosomes is that a class originates from endocytosis system and is discharged from extracellular, the duplicature vesicle of diameter between 40-100nm.Exosomes can be secreted by the various kinds of cell including dendritic cell, tumor cell etc.Contain a large amount of and its source and the closely-related protein of function and lipid components, as the important carrier of iuntercellular transmission of information, participate in multiple pathophysiological process.The exosomes in tumor cell source contains the important immune molecule such as HLA-G, hot body gram albumen, can show antineoplastic action by number of ways, and it is as a kind of novel tumor vaccine, has obvious advantage compared with DC vaccine.
Exosomes is by intracellular multivesicular body (multivesicular bodies, MVB) after merging with cell membrane, be discharged into the vesicle in extracellular environment, can be secreted by various kinds of cell, as dendritic cell, B cell, T cell, mastocyte, tumor cell etc.Exosomes can antigen expressed present correlation molecule MHCI and mhc class ii molecule, and with relevant tumor antigen information, has HLA-II antigen.The contained albumen difference of exosomes of different cell deriveds, its function is not identical yet.Exosomes is except containing cell nonspecific proteins composition, also contain tumor antigen as MAGE, molecular chaperones-heat shock protein (heat shock protein in NY-ESO-1 and antigen presentation process, HSP), can be used as new tumor antigen, be and pass DC and activate and produce tumour-specific CD8
+t cell immune response, and this immunological effect has cross-fire treatment effect.In addition, exosomes is acellular structure, and physicochemical property is stable, high temperature resistant, can Quality Control when preparation, has more superiority compared with cellularity tumor vaccine.
But, but there are in recent years some related experiment to show, the exosomes in some tumors source can suppress or even destroy the immunocyte playing a role in tumor, such as lowering the expression of some NK receptors, have influence on the activation of some inherent immunity cells in tumour immunity, thereby what also have can significantly suppress the propagation that IL-2 suppresses Human Lymphocytes, thereby in the immunization therapy of tumor, plays some negative effects.These exosomes that originated by tumor may be exactly the key factor that tumor tissues escape body immune system is removed, and bring a lot of difficulties and challenge to the immunization therapy of tumor.Therefore, how to improve the immunostimulatory potency of tumor cell source exosomes, and the immunosuppressant ability that reduces it there is great practical significance in the immunization therapy of tumor.
The invention process hepatoma cell line H22 cell and obtain the exosomes of its secretion with procaine associating MS-275, result shows, without the hepatoma carcinoma cell H22 secretion of pharmaceutical composition processing of the present invention nanoscale vesicles---exosomes has significant inhibitory action to the proliferative function of lymphocyte; And can significantly improve this inhibitory action through the exosomes of pharmaceutical composition processing hepatoma cell line H22 of the present invention emiocytosis.Pharmaceutical composition provided by the invention significantly improves exosomes treatment tumor effect, has important clinical value.
Summary of the invention
The object of the present invention is to provide a kind of medical composition and its use.
The object of the present invention is to provide a kind of pharmaceutical composition, described pharmaceutical composition comprises dnmt rna inhibitor and Antibiotic FR 901228.
As the ABC of this area, dnmt rna inhibitor refers to and can suppress dnmt rna activity, and the high methylation of blocking dna suppresses or kill the compound of tumor cell.The dnmt rna inhibitor of researching and developing is more, and its chemical constitution mainly contains nucleoside and the large class of non-nucleoside two, is divided into by mechanism of action: mix DNA and with dnmt rna covalent bond; The noncovalently avtive spot of blocking dna transmethylase; Disturb the binding site of dnmt rna and DNA; Suppress the gene expression of dnmt rna etc.
As the ABC of this area; Antibiotic FR 901228 refers to acetylation and the deacetylation of the lysine residue by regulating histone N-end, activates antioncogene, suppresses cancer gene; thereby inhibition tumor cell growth, a compounds of inducing apoptosis of tumour cell.
Described drug treating tumor cell preferably adopts common dnmt rna inhibitor (DNAmethyltransferase inhibitor, DNMTi) to process.Common dnmt rna inhibitor comprises but is not limited to: azacitidine (5-azacytidine), decitabine (having another name called decitabine decitabine), Zebularine, 5-F-CdR, Hydralazine, SGI-1027, RG108, EGCC, procainamide (procainamide), procaine (procaine), MG-98, Psammaplin A, curcumin (curcumin) etc.
Described drug treating tumor cell preferably adopts common Antibiotic FR 901228 (histone deacetylase inhibitor, HDACi) to process.Common Antibiotic FR 901228 includes but not limited to: butanoic acid, valeric acid and benzenebutanoic acid and salt compounds thereof, trichostatin (trichostatin A, TSA), MS-275 (suberoylanilide hydroxamic), NVP-LAQ824, Pyroxamide, CBHA, Oxamflatin, Scriptaid, MM232, Trapoxin, Apicidin, FK228, WF3161, CHAP31, HC-toxin, LBH589, PDX-101, Tubacin, ACY-1215, MGCD0103, MS-275, Pomidepsin, Plitidepsin etc.
Further pharmaceutical composition preferred dnmt rna inhibitor procaine and Antibiotic FR 901228 MS-275.
Further preferred pharmaceutical compositions dnmt rna inhibitor procaine and Antibiotic FR 901228 MS-275 mol ratio 1: 1.
The invention provides a kind of preparation method of exosomes tumor vaccine, comprise drug treating tumor cell, the exosomes of isolation and purification tumor cell secretion.
Further preferably adopt the pharmaceutical composition that contains procaine and MS-275 to process tumor cell and obtain exosomes tumor vaccine.
Further, described tumor cell comprises ovarian cancer cell, melanoma cell, breast cancer cell, lung carcinoma cell, stomach cancer cell, colon cancer cell, hepatoma carcinoma cell, transitional cell bladder carcinoma cell line, leukaemia or glioma cell.
Preferably after dosing, after 12-48 hour, collect supernatant, more preferably after 24 hours, collect supernatant.
Preferably making the particle diameter of collected exosomes by feasible method is the microparticle of 40-100 nanometer substantially.Preferred, the tumor cell culture supernatant of collecting is removed to cell with the centrifugal 10min of 300g, get supernatant; Remove cell debris with the centrifugal 30min of 1500g, collect supernatant, by 100kU MWCOCentriplus centrifugal ultrafiltration pipe ultrafiltration concentration, obtain 6ml concentrated solution with the centrifugal 30min of 1500g, the concentrated solution of separation and purification is moved in the centrifuge tube of 1.5ml, contain exosomes with level angle with 100kg ultracentrifugation 60min gained precipitation at 4 ℃.
The preparation method of preferred exosomes tumor vaccine, comprising: the DMEI culture fluid containing 100ml/L hyclone for tumor cell, and at 37 ℃ of 50ml/L CO
2in incubator, cultivate, cell is monolayer adherence growth, and every 3-4 days goes down to posterity 1 time, until Growth of Cells during to logarithmic (log) phase, by 3 × 10
6/ 100ml inoculation; Inoculation 24h after with 1 × 10
-6the pharmaceutical composition processing of mol/L, after dosing, 24h collects culture supernatant respectively, and 4 ℃ of preservations.The tumor cell culture supernatant of collecting is removed to cell with the centrifugal 10min of 300g, get supernatant; Remove cell debris with the centrifugal 30min of 1500g, collect supernatant, by 100kU MWCO Centriplus centrifugal ultrafiltration pipe ultrafiltration concentration, obtain 6ml concentrated solution with the centrifugal 30min of 1500g, the concentrated solution of separation and purification is moved in the centrifuge tube of 1.5ml, contain exosomes with level angle with 100kg ultracentrifugation 60min gained precipitation at 4 ℃.
Tumor vaccine provided by the invention can be any dosage form and medication specification that is suitable for clinical practice, for example, can be injection.The preparation method of described tumor vaccine also comprises according to conventional vaccine preparation method makes needed dosage form, for example, make injection, can be by adding normal saline to make injection, also can make injectable powder etc.
Further, exosomes tumor vaccine adds corresponding adjuvant.
Further, described adjuvant is aluminium adjuvant.
Tumor vaccine provided by the invention can, by subcutaneous or administered intramuscular, carry out immunity to individuality, occurs or killing tumor cell to suppress tumor.
The invention provides described tumor vaccine in the application of preparing in antitumor drug.
Further described antitumor can be one or more of anti-leukemia, osteocarcinoma, lymphatic cancer, intestinal cancer, hepatocarcinoma, gastric cancer, pelvic cancer, pulmonary carcinoma, the brain cancer, neural cancer, breast carcinoma, esophageal carcinoma, renal carcinoma.
Further described antitumor is anti-hepatocarcinoma.
Scheme provided by the invention has the following advantages:
(1) the tumor vaccine spectrotype that prepared by pharmaceutical composition provided by the invention extensively, comprehensively, can be realized effectively killing and wounding nearly all tumor cell.
(2) tumor vaccine that prepared by pharmaceutical composition provided by the invention, little to the toxic and side effects of body, use safety.
(3) tumor vaccine that prepared by pharmaceutical composition provided by the invention, can be used as therapeutic vaccine and also can be used as preventative vaccine, use in different oncotherapy stage, by activating body immune system, the generation of prophylaxis of tumours or existing tumor cell is is effectively killed and wounded.
Accompanying drawing explanation
Fig. 1 exosomes corpusculum Electronic Speculum figure
The specific embodiment
Describe embodiments of the invention below in detail only for explaining the present invention; and can not be interpreted as limitation of the present invention; should be understood that; for those skilled in the art; under the premise without departing from the principles of the invention; can also make some improvement, these improve and also should be considered as protection scope of the present invention.
Embodiment 1 cell culture
Experiment material: H22 cell strain, 10% hyclone, mycillin mixed liquor (Beijing company of Tag U.S.).
Experimental technique: H22 cell strain is incubated in the culture fluid containing 10% hyclone, penicillin 100IU/mL, streptomycin 10O × μ g/mL, at 37 ℃ of 5%CO
2in incubator, cultivate, until Growth of Cells during to logarithmic (log) phase, by 3 × 10
6/ 100ml inoculation.
Embodiment 2 drug treating
Experiment material: procaine, MS-275 (all purchased from sigma company).
Experiment grouping: every group of strict conformance of cell culture fluid volume, blank group, exosomes matched group (not dosing group), exosomes experimental group 1 (dosing procaine), exosomes experimental group 2 (dosing MS-275), exosomes experimental group 3 (procaine and MS-275 associating dosing).
Experimental technique: matched group, after inoculation, do not add medicine, after 24h, collect supernatant 150ml in contrast; Dosing group 1, uses concentration 1 × 10 after inoculation 24h
-6the procaine processing of mol/L, after dosing, 24h collects the each 150ml of culture supernatant respectively; Dosing group 2, uses concentration 1 × 10 after inoculation 24h
-6the MS-275 of mol/L processes, and after dosing, 24h collects the each 150ml of culture supernatant respectively; Dosing group 3, inoculation 24h after with 1 × 10
-6the procaine of mol/L and 1 × 10
-6the MS-275 of mol/L processes, and after dosing, 24h collects the each 150ml of culture supernatant respectively, and 4 ℃ of preservations.
The isolation and purification of embodiment 3exosomes
Experimental apparatus: HMAC-CP70G low temperature ultrahigh speed centrifuge, 100KU MW CO Millipore Amicon high-recovery high flow rate cross-flow ultrafiltration centrifuge tube (Millipore company).
Experimental technique: the experimental group of collecting and cellular control unit culture supernatant are removed to cell with the centrifugal 10min of 300g, get supernatant; Remove cell debris with the centrifugal 30min of 1500g, collect supernatant, by 100kUMWCO Centriplus centrifugal ultrafiltration pipe ultrafiltration concentration, obtain 6ml concentrated solution with the centrifugal 30min of 1500g, the concentrated solution of separation and purification is moved in the centrifuge tube of 1.5ml, contain exosomes with level angle with 100kg ultracentrifugation 60min gained precipitation at 4 ℃.
The Electronic Speculum of embodiment 4exosomes is identified
Drip 20-30 μ l exosomes suspension on load sample copper mesh, room temperature leaves standstill lmin and blots liquid with filter paper from side, drip 20ml/L Salkowski's solution (pH6.8) approximately 30 μ l on copper mesh, room temperature negative staining lmin filter paper blots negative staining liquid, dries under about lOmin transmission electron microscope and observe and take a picture under room temperature.Result as shown in Figure 1.The film microcapsule structure that the exosomes corpusculum diameter of H22 emiocytosis under Electronic Speculum is 30-80nm, rounded or oval, intracavity is low electron density composition.(increasing description and the discussion of result)
The embodiment 5H3-TdR method of mixing detects PBMC cell proliferation situation
Experiment material: H
3-TdR (Shanghai nuclear research institute), mycillin mixed liquor (Beijing company of Tag U.S.), hyclone
Experimental apparatus: β-liquid scintillation counter measurement (FJ-2107G type)
Experiment grouping: blank group (only adding phytohemagglutinin and PBMC cell), exosomes matched group (not dosing group), exosomes experimental group 1 (dosing procaine), exosomes experimental group 2 (dosing MS-275), exosomes experimental group 3 (procaine and MS-275 associating dosing), supernatant matched group (not dosing group) after exosomes extracts, supernatant experimental group 1 (dosing procaine) after exosomes extracts, supernatant experimental group 2 (dosing MS-275) after exosomes extracts, supernatant experimental group 3 (procaine and MS-275 associating dosing) after exosomes extracts, every component is three multiple holes.
Experimental technique: the PBMC cell of separator well adds 5ml to contain the fresh RPMI1640 culture medium of 10% hyclone, after cell counting, dilution is 5000/50 microlitres, according to previous ready-made labelling, add in 96 orifice plates with 50 microlitres/hole, add the mixed liquor of penicillin 100IU/mL, streptomycin 10O × μ g/mL with the ratio of 1: 1000, then add 50 μ l samples, finally add 100 μ lIPHA simultaneously.Put into 37 ℃ of 50%CO
2incubator spends the night, second day can lO × inverted microscope under observe PBMC cell and be bulk propagation, by H
3-TdR adds in culture plate, every hole 3.7 × 10
4individual Bq continues to cultivate after 6h, goes culture medium, washes 3 times with 1 × PBS, and the NaOH broken cell film of lmol/L, adds scintillation solution and appropriate anti-quencher, with β-liquid scintillation counter measurement, records cpm value (minute count).Result is as shown in table 1.
The impact of the supernatant of table 1 through the exosomes before and after combination medicine is processed and after extracting on PBMC cell proliferation
| Group | Group number | Cpm value (X ± S) |
| Blank | 3 | 24016±2001.25 |
| Exosomes matched group | 3 | 3635±19.98 |
| Exosomes experimental group 1 | 3 | 19012±775.62 |
| Exosomes experimental group 2 | 3 | 19125±763.51 |
| Exosomes experimental group 3 | 3 | 23768±701.21 |
| Supernatant matched group after exosomes extracts | 3 | 2987±501.99 |
| Supernatant experimental group 1 after exosomes extracts | 3 | 21532±6482.36 |
| Supernatant experimental group 2 after exosomes extracts | 3 | 20461±6621.89 |
| Supernatant experimental group 3 after exosomes extracts | 3 | 23998±6006.21 |
Result shows: compared with blank group,, after the exosomes and PBMC co-culture of cells of drug treating, lymphopoiesis is not had to appreciable impact, obviously reduce (P < 0.05), through drug treating, can obviously improve the inhibition of exosomes to the proliferative function of lymphocyte, the inhibition minimum of the exosomes (exosomes experimental group 3) wherein obtaining after pharmaceutical composition is processed to the proliferative function of lymphocyte, be significantly less than after drug alone is processed and obtain exosomes (exosomes experimental group 1 and exosomes experimental group 2) to lymphopoietic inhibition, there is significant difference (P < 0.05) in PBMC propagation value and exosomes matched group comparative statistics, compare without significant difference (P > 0.05) with blank group.At experimental group, after the supernatant and PBMC co-culture of cells of the drug treating after exosomes extracts, on cell proliferation is almost without impact, with relatively significantly significant difference (P > 0.05) of nothing of blank group, supernatant without drug treating has a significant impact the proliferative function of lymphocyte, and statistically all there were significant differences compared with blank group or supernatant experimental group (P < 0.05).
Tumor suppression experiment in embodiment 6 bodies
Experiment material: healthy kunming mouse, murine hepatocarcinoma cell (H22), RPMI1640 culture medium (purchased from GIBCO), hyclone
Experimental technique:
(1) set up mice with tumor model: H22 mouse ascites is got by sterile working, Trypan Blue, oncocyte counting under light microscopic, the oncocyte 9000 of living, adjusting cell concentration is 1 × 10
7individual/ml, in every the right axil subcutaneous vaccination of mice 0.2ml, makes solid type mice with tumor model.
(2) prepare tumor vaccine: carry out cell culture according to described embodiment 1; Cultured cells is divided into 4 groups, first group of not dosing, second group of dosing procaine, the 3rd group of dosing MS-275, the 4th group of procaine and MS-275 associating dosing, concrete dosing is processed with reference to embodiment 2; The each group of cell culture supernatant of collecting prepared to exosomes tumor vaccine with reference to embodiment 3.
(3) grouping and treatment: 30 of mices are divided into 5 groups at random, every group each 6.Blank group: tumor-bearing mice intraperitoneal injection of saline; Exosomes matched group: tumor cell inoculation same day, in first group of tumor vaccine of preparing of mice lower limb root subcutaneous injection (10 μ g/ are only); Exosomes experimental group 1: tumor cell inoculation same day, in second group of tumor vaccine of preparing of mice lower limb root subcutaneous injection (10 μ g/ are only); Exosomes experimental group 2: tumor cell inoculation same day, in the 3rd group of tumor vaccine of preparing of mice lower limb root subcutaneous injection (10 μ g/ are only); Exosomes experimental group 3: tumor cell inoculation same day, in the 4th group of tumor vaccine of preparing of mice lower limb root subcutaneous injection (10 μ g/ are only).At interval of repetition in 1 day 1 time, totally 3 times.All mices are put to death for the 15th day after inoculated tumour, get tumor body, weigh, survey gross tumor volume, calculate the heavy suppression ratio of tumor, gross tumor volume suppression ratio.
(4) take tumor weight and calculate tumor control rate
Mice is taken out respectively tumor tumor body after putting to death, and after peeling off totally, wipes clean blood stains with filter paper, and electronic balance takes tumor weight, calculates tumour inhibiting rate:
Tumour inhibiting rate (%)=(matched group tumor size-treatment group tumor size)/matched group tumor size × 100%.
The inhibitory action of table 2 tumor vaccine to transplanted human hepatocellular carcinoma
| Experiment grouping | Tumor average quality |
| Blank group | 2.78±0.29 |
| Exosomes matched group | 1.76±0.16 |
| Exosomes experimental group 1 | 1.32±0.14 |
| Exosomes experimental group 2 | 1.29±0.17 |
| Exosomes experimental group 3 | 0.97±0.13 |
After adopting exosomes tumor vaccine therapy, Growth of Transplanted Hepatocarcinoma in Mice is suppressed, exosomes experimental group 1, exosomes experimental group 2, exosomes experimental group 3 tumor quality are respectively (1.32 ± 0.14) g, (1.29 ± 0.17) g, (0.99 ± 0.13) g, with blank group (2.78 ± 0.29) g, exosomes matched group, (1.76 ± 0.16) g is than significant difference (P < 0.05), tumor vaccine inhibitory action prepared by procaine and MS-275 associating dosing is the strongest, tumor quality is (0.99 ± 0.13) g, inhibitory rate 65.11%.
The invention provides a kind of pharmaceutical composition, uses this pharmaceutical composition to process tumor cell, and the exosomes of tumor cell secretion after treatment can significantly improve the inhibitory action of former exosomes to the proliferative function of lymphocyte.Zoopery shows, adopts pharmaceutical composition of the present invention to process the exosomes tumor vaccine therapy effect of preparing remarkable, has important clinical value.
Claims (10)
1. a pharmaceutical composition, described pharmaceutical composition comprises dnmt rna inhibitor and Antibiotic FR 901228, it is characterized in that, described dnmt rna inhibitor can be selected from one or more in following medicine: azacitidine (5-azacytidine), decitabine (having another name called decitabine decitabine), Zebularine, 5-F-CdR, Hydralazine, SGI-1027, RG108, EGCC, procainamide (procainamide), procaine (procaine), MG-98, PsammaplinA, curcumin (curcumin), described Antibiotic FR 901228 can be selected from one or more in following medicine: butanoic acid, valeric acid and benzenebutanoic acid and salt compounds thereof, trichostatin (trichostatin A, TSA), MS-275 (suberoylanilide hydroxamic), NVP-LAQ824, Pyroxamide, CBHA, Oxamflatin, Scriptaid, MM232, Trapoxin, Apicidin, FK228, WF3161, CHAP31, HC-toxin, LBH589, PDX-101, Tubacin, ACY-1215, MGCD0103, MS-275, Pomidepsin, Plitidepsin.
2. pharmaceutical composition according to claim 1, is characterized in that, described dnmt rna inhibitor is procaine; Described Antibiotic FR 901228 is MS-275.
3. according to the pharmaceutical composition described in claim 1-2 any one, it is characterized in that, described dnmt rna inhibitor and Antibiotic FR 901228 ratio are 1: 1.
In claim 1-3 the pharmaceutical composition described in any one in the purposes of preparing in tumor vaccine.
5. a method of preparing tumor vaccine, is characterized in that, described method comprises: right to use requires the pharmaceutical composition described in 1-3 any one to process tumor cell; The exosomes of isolation and purification tumor cell secretion.
6. the method for preparing tumor vaccine according to claim 5, comprising: the DMEI culture fluid containing 100ml/L hyclone for tumor cell, and at 37 ℃ of 50ml/L CO
2in incubator, cultivate, cell is monolayer adherence growth, and every 3-4 days goes down to posterity 1 time, inoculates during to logarithmic (log) phase until Growth of Cells; After inoculation 24h, process cell with the pharmaceutical composition described in claim 1-3 any one, after dosing, 24h collects culture supernatant respectively, and 4 ℃ of preservations; By centrifugal the tumor cell culture supernatant of collecting removal cell, get supernatant; Centrifugal removal cell debris again, collect supernatant, by 100kU MWCO Centriplus centrifugal ultrafiltration pipe ultrafiltration concentration, the centrifugal concentrated solution that obtains, the concentrated solution of separation and purification is moved in the centrifuge tube of 1.5ml, at 4 ℃, use level angle with 100kg ultracentrifugation, gained precipitation contains exosomes.
7. the tumor vaccine making according to the method for preparing tumor vaccine described in claim 5-6 any one.
8. tumor vaccine as claimed in claim 7, is characterized in that, described tumor vaccine comprises adjuvant.
9. the tumor vaccine as described in claim 7-8 any one is in the application of preparing in antitumor drug.
10. application as claimed in claim 9, is characterized in that, described antitumor drug is medicines resistant to liver cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410075924.8A CN103861107B (en) | 2014-03-04 | 2014-03-04 | Pharmaceutical composition and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410075924.8A CN103861107B (en) | 2014-03-04 | 2014-03-04 | Pharmaceutical composition and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103861107A true CN103861107A (en) | 2014-06-18 |
| CN103861107B CN103861107B (en) | 2015-01-14 |
Family
ID=50900491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410075924.8A Expired - Fee Related CN103861107B (en) | 2014-03-04 | 2014-03-04 | Pharmaceutical composition and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103861107B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021139697A1 (en) * | 2020-01-07 | 2021-07-15 | 祝康生物科技有限公司 | Application of supernatant of tumor cells after action of chemotherapeutic drug |
| CN114908049A (en) * | 2021-02-10 | 2022-08-16 | 江苏集萃医学免疫技术研究所有限公司 | Use of HDAC6 inhibitors to selectively induce T cell expansion |
| US11413339B2 (en) | 2019-05-05 | 2022-08-16 | Hainan Medical University | Whole-cell tumor vaccine based on principle of extracellular trap and method of making same |
| CN115819602A (en) * | 2022-12-09 | 2023-03-21 | 北京高科创航科技有限公司 | Pharmaceutical composition with proliferation and apoptosis regulating effect on cells and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102088969A (en) * | 2008-06-09 | 2011-06-08 | 西克拉塞尔有限公司 | Combination of spacitabine (CNDAC) and DNA methyltransferase inhibitors such as decitabine and procaine |
-
2014
- 2014-03-04 CN CN201410075924.8A patent/CN103861107B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102088969A (en) * | 2008-06-09 | 2011-06-08 | 西克拉塞尔有限公司 | Combination of spacitabine (CNDAC) and DNA methyltransferase inhibitors such as decitabine and procaine |
Non-Patent Citations (2)
| Title |
|---|
| 董伟伟 等: "exosomes：肿瘤免疫治疗新进展", 《医学研究杂志》 * |
| 董伟伟 等: "外体（exosomes）在肿瘤免疫治疗中的应用", 《生物技术通讯》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11413339B2 (en) | 2019-05-05 | 2022-08-16 | Hainan Medical University | Whole-cell tumor vaccine based on principle of extracellular trap and method of making same |
| WO2021139697A1 (en) * | 2020-01-07 | 2021-07-15 | 祝康生物科技有限公司 | Application of supernatant of tumor cells after action of chemotherapeutic drug |
| CN114908049A (en) * | 2021-02-10 | 2022-08-16 | 江苏集萃医学免疫技术研究所有限公司 | Use of HDAC6 inhibitors to selectively induce T cell expansion |
| CN115819602A (en) * | 2022-12-09 | 2023-03-21 | 北京高科创航科技有限公司 | Pharmaceutical composition with proliferation and apoptosis regulating effect on cells and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103861107B (en) | 2015-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20150086639A1 (en) | Tumor vaccine and method for producing the same | |
| KR20180042284A (en) | Smallpox vaccine for use in cancer treatment | |
| CN103861107B (en) | Pharmaceutical composition and uses thereof | |
| CN103816535B (en) | Tumour vaccine and preparation method thereof | |
| CN105848662A (en) | Tumoricidal and antimicrobial compositions and methods | |
| CN105886469B (en) | CIK cell and its cultural method and application | |
| CN101361732B (en) | Medicinal preparation containing garcinia acid and use thereof | |
| JP2010220479A (en) | Method for culturing nk cell and use of the same | |
| CN105288603A (en) | Tumor vaccine for treating liver cancer and preparing method thereof | |
| KR20210016995A (en) | Exosome derived from radiated cancer cell, cancer vaccine comprising dendritic cell prepared by using the same and preparing method thereof | |
| CN105031631A (en) | Preparation method and application of HLA-A0201-restrictive anti-Sox2 specific CTL | |
| CN107708728A (en) | It is a kind of to be used to treat tumor vaccine of stomach cancer and preparation method thereof | |
| JP2019031470A (en) | Antitumor composition containing nk cell conditioned medium and method for producing the same | |
| CN113117088A (en) | Use of calcium-activated chloride channel inhibitors in tumor immunotherapy | |
| WO2013155885A1 (en) | Application of lucide ganoderma and ginseng medicinal mycoplasm in preparing drugs for treating lung cancer | |
| CN112138018A (en) | Application of dendrobium officinale polysaccharide in preparation of medicine for treating tumors by targeting tumor-related macrophages | |
| RU2379055C1 (en) | Method of treating oncological diseases | |
| AU2003277641B2 (en) | Remedy for cancer | |
| CN102440994A (en) | Application of ganoderic acid G as immune synergist and super-antigen dependent therapeutic medicine in tumour treatments | |
| Sun et al. | IMMU-28. TREM2 INHIBITION REPROGRAMS MYELOID CELLS TO STIMULATE ANTI-TUMOR IMMUNITY THROUGH BOTH DIRECT AND INDIRECT MECHANISMS | |
| CN102309493B (en) | Anti-cancer medicinal composition | |
| CN103169693A (en) | Application of wogonin derivant in preparation of drug for treating liver cancer | |
| Mallmann | Tumor vaccination | |
| Schultz et al. | Immunotherapy with allogeneic immune peritoneal cells activated by BCG or pyran copolymer | |
| CN101912599A (en) | Application of recombinant human interleukin 15 in preparing medicament for treating malignant ascitic tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: NO.1 HOSPITAL ATTACHED TO PLA GEN. HOSPITAL Free format text: FORMER OWNER: XIAO WENHUA Effective date: 20140904 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20140904 Address after: 100048 Beijing city Haidian District Fuchengmen Road No. 51 Applicant after: The First Affiliated Hospital of General Hospital of PLA Address before: 100048 Beijing city Haidian District Fuchengmen Road No. 51 Applicant before: Xiao Wenhua |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150114 Termination date: 20190304 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |